Lanton Law Moderates Most Favored Nation Panel for MJH Life Sciences

Lanton Law was honored to be selected as a moderator for the MJH Life Sciences panel titled ““Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”

The AJMC wrote a nice blog post on the panel. The panelists, included moderator Ron Lanton, JD, of Lanton Law; Mel Whittington, PhD, managing director and head of the Leerink Center for Pharmacoeconomics at MEDACorp, Inc.; Stephen Forster, JD, partner at the Health Care and Life Sciences Practice at Jones Day; and Peter Rubin, executive director of No Patient Left Behind. The panel discussed the voluntary Pfizer agreement, which aims to reduce prices by up to 85%, and the new TrumpRx platform, set to launch in 2026 to allow direct-to-consumer medication purchases.

The Pharmaceutical Executive story on the panel can be found here.

The AJMC article on the panel can be viewed here.

Lanton Law Quoted in Pharmacy Times Interview on Drug Pricing Reforms Amid the Repeal of Executive Order 14087

Lanton Law was quoted in the Pharmacy Times Article titled "Reversal of Executive Order (EO) 14087 Raises Questions About Future Drug Pricing Reforms.” We discuss the EO and how pharmacists are impacted. The article can be viewed here.

Biden Administration Announces First Ten Drugs Selected for Medicare Price Negotiation

The Biden Administration has announced today that Medicare will be able to negotiate drug prices for the first time due to provisions within the Inflation Reduction Act. 

The first ten selected drugs for negotiation are Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp. 

The Administration stated that these drugs “accounted for $50,5 billion in total Part D gross covered prescription drug costs. The negotiations will occur in 2023 and 2024 and any negotiated prices will become effective beginning in 2026. 

According to HHS press release read here, “In future years, CMS will select for negotiation up to 15 more drugs covered under Part D for 2027, up to 15 more drugs for 2028 (including drugs covered under Part B and Part D), and up to 20 more drugs for each year after that, as outlined in the Inflation Reduction Act.”

Lanton Law is a national boutique law and government affairs firm that closely monitors legislative, regulatory and legal developments in the healthcare and life science spaces. Contact us to learn about how either our legal or lobbying services can help you attain your goals.

What are the clean energy elements discussed within the Inflation Reduction Act (IRA)?

The IRA invests $369 billion in clean energy and energy efficiency programs. This investment is designed to reduce the United States' reliance on foreign oil and bring down energy prices. The clean energy sections of the IRA include:

• Extending and expanding the Production Tax Credit (PTC) and Investment Tax Credit (ITC) for renewable energy. These tax credits make it more affordable for businesses to invest in renewable energy projects.

• Investing in clean energy research and development. This investment will help to accelerate the development of new clean energy technologies.

• Creating a new Clean Electricity Performance Program. This program will reward utilities for generating electricity from clean sources.

• Investing in energy efficiency programs. This investment will help to reduce energy consumption and save consumers money on their energy bills.

The IRA is expected to create millions of new jobs in the clean energy sector. The law is also expected to reduce the federal budget deficit and increase economic growth.

Here are some of the key takeaways from the clean energy sections of the IRA:

• The IRA is the largest piece of legislation ever to address climate change.

• The IRA is expected to create millions of new jobs and reduce the federal budget deficit.

• The IRA is still in its early stages of implementation, but it is expected to make a positive contribution to reducing inflation and growing the economy.

Here are some specific examples of how the IRA is expected to help the clean energy sector:

• The extension and expansion of the PTC and ITC are expected to spur investment in solar, wind, and other renewable energy projects.

• The investment in clean energy research and development is expected to help to accelerate the development of new clean energy technologies, such as carbon capture and storage.

• The Clean Electricity Performance Program is expected to reward utilities for generating electricity from clean sources, such as solar and wind.

• The investment in energy efficiency programs is expected to help to reduce energy consumption and save consumers money on their energy bills.

The IRA is a significant piece of legislation that is expected to have a major impact on the clean energy sector. The law is still in its early stages of implementation, but it is expected to make a positive contribution to reducing emissions and growing the economy.

Lanton Law is a national boutique law and government affairs firm that closely monitors legislative, regulatory and legal developments in the clean energy space. Contact us to learn about how either our legal or lobbying services can help you attain your goals.

More Drugmakers Sue Biden Administration Over Medicare Negotiation

Johnson and Johnson has filed a lawsuit in New Jersey federal district court, arguing that the new powers granted to Medicare to negotiate drug prices violate the First and Fifth Amendments of the U.S. Constitution. Medicare’s new power to negotiate comes from the recently enacted Inflation Reduction Act (IRA). Earlier suits by Merck, Bristol Myers Squibb, the U.S. Chamber of Commerce and PhRMA have made similar arguments.

As part of the new law, the Centers for Medicare and Medicaid Services (CMS) will publish a list of which drugs were selected for a first cycle of negotiations on Sept. 1, with prices taking effect in 2026. The companies that make those drugs face an October deadline to sign agreements to participate in those negotiations.

Lanton Law is a national boutique law and government affairs firm that closely monitors legislative, regulatory and legal developments in the healthcare and life science spaces. Contact us to learn about how either our legal or lobbying services can help you attain your goals.

Lanton Law Speaks at Summit & Reverse Expo

We were pleased to be invited to Orlando, Florida to speak with IDN with our presentation titled “Price, Innovation & Policy: What’s on the Horizon for the Industry.